LifeVantage Corporation shares fell 10.2% in after-hours trading to $5.79 after the health and wellness company reported fourth-quarter and fiscal 2026 results. Fourth-quarter revenue declined 23.1% year over year to $42.4 million, below the $44.4 million analyst estimate, while adjusted earnings per share was $0.11 against a $0.13 consensus. Full-year revenue fell 20.1% to $182.6 million and adjusted EPS declined to $0.56 from $0.82. The company attributed the quarterly decline to lower order volumes from its active account base, smaller average orders, weaker demand for the higher-priced MindBody GLP-1 System and a pullback in consumer spending. LoveBiome, acquired in October 2025, partly offset the weakness. Terrence Moorehead, who recently joined as president and chief executive officer, identified brand strengthening, a more relevant consumer proposition, and improved operational efficiency and profitability as initial priorities. LifeVantage declined to provide formal fiscal 2027 guidance during the leadership transition, although management expects challenging first- and second-quarter comparisons and potential momentum improvement in the second half. The company ended fiscal 2026 with $14.9 million in cash and no debt, repurchased about 336,000 shares for $2 million, and declared a quarterly dividend of $0.05 per common share.